Iberdomide is a modulator of the cullin ring ligase 4-cereblon E3 ubiquitin ligase complex with higher affinity (IC50 = 60 nM) than lenalidomide and pomalidomide leading to more potent degradation of Ikaros (IKZF1, EC50 = 1 nM)) and Aiolos (IKZF3, EC50 = 0.5 nM).1 It is more specific for the cereblon complex and does not degrade GSPT1 of CK1alpha. It displays antitumor and immunostimulatory activity in lenalidomide- and pomalidomide-resistant multiple myeloma cells.2 Iberdomide has also shown efficacy in treating the autoimmune disease cutaneous lupus erythematosus (CLE).3 It was also shown to act as an HIV-1 latency reversal agent in in CD4+ T-cells.4
* VAT and and shipping costs not included. Errors and price changes excepted
